Satsuma Pharmaceuticals
South San Francisco
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $154.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2021)
- Ticker: nasdaq:STSA
- Website: satsumarx.com
- Phone: 650.410.3200
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/satsuma-pharmaceuticals-133447 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.